WST
WEST PHARMACEUTICAL SERVICES INC
NYSE · Healthcare · Medical - Instruments & Supplies · US
$409.07
+0.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.4B | 3.1B | 2.9B | 3.0B | 2.9B |
| Cost of Revenue | 2.1B | 2.0B | 1.9B | 1.8B | 1.7B |
| Gross Profit | 1.3B | 1.1B | 1.0B | 1.1B | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 75.6M | 74.3M | 69.1M | 68.4M | 58.5M |
| SG&A Expense | 436.5M | 393.1M | 338.5M | 353.4M | 316.9M |
| General & Admin Expense | 230.5M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (15.9M) | 18.5M | — | — | — |
| Total Operating Expenses | 496.2M | 485.9M | 407.6M | 421.8M | 375.4M |
| Cost and Expenses | 2.6B | 2.5B | 2.3B | 2.2B | 2.1B |
| Operating Income (EBIT) | 780.2M | 617.4M | 594.6M | 710.9M | 763.5M |
| Non-Operating | |||||
| Interest Income | 10.2M | 17.7M | 19.6M | 28.0M | 5.1M |
| Interest Expense | — | 600.0K | 2.9M | 8.8M | 7.6M |
| Net Interest Income | 10.2M | 17.1M | 16.7M | 19.2M | (2.5M) |
| Other Non-Op Income/Expense | 13.1M | (2.1M) | 5.6M | 4.8M | (62.9M) |
| Non-Operating Income (excl Interest) | (3.0M) | 18.2M | 6.2M | 4.1M | 76.0M |
| EBT (Pre-Tax Income) | 793.3M | 615.3M | 600.2M | 715.7M | 700.6M |
| Income Tax Expense | 168.2M | 121.6M | 107.5M | 122.3M | 114.7M |
| Bottom Line | |||||
| Net Income | 638.9M | 493.7M | 492.7M | 593.4M | 585.9M |
| Earnings from Cont. Ops | 625.1M | 493.7M | 492.7M | 593.4M | 585.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 638.9M | 493.7M | 492.7M | 593.4M | 585.9M |
| Per Share | |||||
| Basic EPS | $8.97 | $6.83 | $6.75 | $7.99 | $7.88 |
| Diluted EPS | $8.91 | $6.80 | $6.69 | $7.88 | $7.73 |
| Revenue Per Share | $48.25 | $42.51 | $39.63 | $39.72 | $38.78 |
| Shares | |||||
| Basic Shares Outstanding | 70.4M | 72.3M | 73.0M | 74.3M | 74.4M |
| Diluted Shares Outstanding | 70.8M | 72.7M | 73.7M | 75.3M | 75.8M |
| Profitability Metrics | |||||
| EBITDA | 966.9M | 770.6M | 743.8M | 844.1M | 808.1M |
| D&A | 183.7M | 171.4M | 155.4M | 137.3M | 120.6M |
| EBIT | 783.2M | 599.2M | 588.4M | 706.8M | 687.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026